Risks of Allergy Shots: Every Known Risk Factor, Explained

Uncontrolled asthma is by far the most important and well-documented risk factor for serious allergy shot reactions. The Bernstein 2004 fatality survey, which analyzed 41 confirmed SCIT deaths from 1990 to 2001, found that 88% of cases with detailed clinical information involved patients with asthma, most of it poorly controlled on the day of the injection. The Amin 2006 near-fatal reaction study found that 40% of near-fatal reactors had baseline FEV1 below 70% predicted. The current Practice Parameter defines FEV1 below 70% predicted as a defined risk factor requiring injection deferral on that day. Patients with asthma who maintain good control have a substantially better safety profile than those with poorly controlled disease. Pre-injection peak flow assessment is recommended for asthmatics at every visit.

Beta-blockers are classified as a relative contraindication for SCIT in the 2011 AAAAI/ACAAI Practice Parameter. The mechanism is pharmacological: beta-adrenergic blockade impairs both bronchodilation and cardiac inotropy in response to epinephrine, making anaphylaxis rescue treatment less effective (Nassiri 2015, JACI). If a severe reaction occurs and epinephrine is administered, the beta-blocked patient's response will be blunted. However, the clinical evidence is nuanced — contemporary venom immunotherapy studies found no increase in reaction frequency or severity in beta-blocker users, leading the 2023 Anaphylaxis Practice Parameter to shift toward shared decision-making when cardiac indications are compelling. For patients on beta-blockers who must continue SCIT, glucagon (1-5 mg IV) is available as a rescue agent that bypasses beta-receptor blockade. Discuss your medication list thoroughly with your allergist.

Yes, peak pollen season elevates per-injection risk through a well-established biological mechanism. Repeated mucosal allergen exposure during a patient's primary pollen season upregulates tissue mast cells, eosinophils, and adhesion molecules — so the same maintenance dose that was well-tolerated out of season can provoke a larger immune response when pollen counts are high. The Epstein 2013 Year 3 surveillance study demonstrated this effect concretely: practices that consistently reduced doses during patients' peak pollen seasons had significantly fewer Grade 2-3 systemic reactions (44% vs. 65%, P=0.04). The historical Lockey 1987 fatality survey found 41% of documented deaths occurred during patients' peak seasons. Standard practice is a 50% dose reduction during peak season for highly sensitized patients, which is a safety measure — not an indication that treatment has stopped working.

New vial transitions are a recognized higher-risk period in SCIT because allergen extract potency can vary between vial batches, even when the labeled concentration is the same. This potency variation means the first few injections from a new vial may deliver a more biologically active dose than the patient's immune system has been conditioned to. The 2011 Practice Parameter recommends a 50% dose reduction at each new vial transition as standard safety protocol. Counterintuitively, surveillance data show that maintenance phase — which uses longer intervals between injections — paradoxically accounted for the majority of historical fatalities, partly because maintenance patients are more likely to experience new vial transitions with longer intervals between doses, reducing conditioned tolerance. Always confirm with your clinic that your new vial protocol includes the recommended dose reduction.

The relationship between large local reactions and systemic reaction risk is more nuanced than simple yes or no. The 2011 Practice Parameter explicitly states that published studies do not indicate a single large local reaction predicts a subsequent systemic reaction — the Tankersley 2000 study found no increase in systemic reaction rates in patients with local reactions given no dose adjustment, and the Kelso 2004 study found equivalent systemic reaction rates with or without dose adjustment after local reactions. However, the picture is not entirely reassuring. Roy 2007 found local reaction rates four-fold higher in patients who had experienced systemic reactions, and the REPEAT Study (Calabria 2011) found 41.7% of patients with frequent, recurrent local reactions experienced at least one systemic reaction over follow-up, compared to 10.7% of non-local-reaction patients. A single large local reaction is not predictive, but a pattern of recurrent large local reactions may identify a higher-risk subset.

The answer depends on which type of risk you mean. Per-injection rates of mild to moderate systemic reactions are higher during build-up, when doses are escalating toward the therapeutic maintenance level. Each incremental dose increase during build-up represents a new immunological challenge. However, severe and fatal reactions have paradoxically shown higher representation during maintenance phase in surveillance data. The Bernstein 2004 fatality survey found 59% of fatalities occurred during maintenance, often associated with new-vial transitions — when a patient returns for a monthly maintenance injection and receives the first dose from a new vial with no dose reduction. This pattern underscores that the risk does not simply decrease once maintenance is reached; new vial transitions require vigilance and dose reduction protocols regardless of the treatment phase.